Sandostatin Related Published Studies
Well-designed clinical trials related to Sandostatin (Octreotide)
Randomised clinical trial: the safety and efficacy of long-acting octreotide in
patients with portal hypertension. [2012]
Is Octreotide Treatment Useful in Patients with Congenital Chylothorax? [2011.11.10]
Octreotide for the treatment of diarrhea in patients with ileal pouch anal anastomosis: a placebo controlled cross-over study. [2011.09.23]
Serum angiotensin I-converting enzyme levels and the therapeutic effects of octreotide in esophageal variceal hemorrhage. [2011.07]
Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. [2011.06]
Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. [2011.03]
Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. [2010.06]
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. [2010.05]
Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. [2010.04.21]
Decreased leg glucose uptake during exercise contributes to the hyperglycaemic effect of octreotide. [2010.03]
A randomized, double-masked controlled clinical trial of Sandostatin long-acting release depot in patients with postsurgical cystoid macular edema. [2010.01]
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. [2010]
A randomized, double-masked controlled clinical trial of Sandostatin long-acting
release depot in patients with postsurgical cystoid macular edema. [2010]
Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. [2009.12]
Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease. [2009.11]
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. [2009.10]
Effect of somatostatin analogue octreotide on pain relief after major abdominal surgery. [2009.09]
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. [2009.08]
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. [2009.07]
Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. [2009.05]
Randomized study of the effect of pentoxifylline or octreotide on serum levels of TNF-alpha and IL-6 after endoscopic retrograde cholangiopancreatography. [2009.05]
Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. [2009.03]
Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache. [2009.02]
Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease. [2009]
Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA. [2008.11.10]
Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. [2008.10]
Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy. [2008.09]
[Splanchnic hemodynamic effects of somatostatin and octreotide in cirrhotic patients. A Doppler ultrasonographic study] [2008.09]
Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: results of a prospective randomized double-blinded placebo-controlled trial. [2008.08]
Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. [2008.04]
Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: Results of a prospective randomized double-blinded placebo-controlled trial. [2008.02.23]
A pilot phase II randomized, cross-over, double-blinded, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end-of-life. [2008]
Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial. [2007.10]
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. [2007.09.03]
Comparison of Octreotide and Standard Therapy Versus Standard Therapy Alone for the Treatment of Sulfonylurea-Induced Hypoglycemia. [2007.08.29]
Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. [2007.08.15]
A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. [2007.07]
Octreotide Enhances Portal Pressure Reduction Induced by Propranolol in Cirrhosis: A Randomized, Controlled Trial. [2007.06.29]
Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. [2007.06.21]
Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer. [2007.05]
Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. [2007.03]
Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. [2007.02]
Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome. [2007.01.19]
Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. [2007.01]
Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. [2007.01]
Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial. [2007.01]
Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. [2006.12]
Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. [2006.11]
Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Release Octreotide for Treatment of Graves' Ophthalmopathy. [2006.09.19]
A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. [2006.06]
The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites. [2006.04]
Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction. [2006.03]
A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. [2006.02]
Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma. [2006.02]
Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy. [2005.10]
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. [2005.10]
A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. [2005.09.13]
Analysis of peripheral blood T-cell subsets in active thyroid-associated ophthalmopathy: absence of effect of octreotide-LAR on T-cell subsets in patients with thyroid-associated ophthalmopathy. [2005.09]
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. [2005.08]
Prospectively randomized trial using perioperative low dose octreotide to prevent organ related and general complications following pancreatic surgery and pancreatico-jejunostomy. [2005.08]
The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. [2005.08]
Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. [2005.07]
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. [2005.07]
Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. [2005.07]
The use of low dose octreotide prophylaxis in pancreatic transplants with enteric drainage. Results of a prospective randomized single center trial. [2005.06]
The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. [2005.04]
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. [2005.03]
Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. [2005.03]
Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. [2005.02]
Sclerotherapy plus octreotide versus sclerotherapy alone in the management of gastro-oesophageal variceal hemorrhage. [2005.01]
Effect of somatostatin versus octreotide on portal haemodynamics in patients with cirrhosis and portal hypertension. [2005.01]
Octreotide is not effective in the acute treatment of migraine. [2005.01]
Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. [2004.12]
Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study. [2004.10]
[Determination of octreotide in human plasma by HPLC-MS with solid-phase extraction and study on the relative bioavailability of domestic and imported octreotide injections] [2004.07]
Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas. [2004.05]
[Octreotide administration and/or endoscopic treatment in cirrhotic patients with acute variceal bleeding: a multicentric study] [2004.03]
The effect of octreotide as an adjunct treatment in active nonvariceal upper gastrointestinal bleeding. [2004.03]
Effect of octreotide administration on serum interleukin-6 (IL-6) levels of patients with acute edematous pancreatitis. [2004.03]
Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicenter randomized controlled trial. [2004.03]
[Effects of acute octreotide infusion on renal function in patients with cirrhosis and portal hypertension] [2004.02]
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. [2004.02]
Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome. [2004.01.01]
[The effects of octreotide on portal hemodynamics in patients with liver cirrhosis] [2004.01]
The somatostatin analogue octreotide impairs sleep and decreases EEG sigma power in young male subjects. [2004.01]
Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. [2003.10]
Long-term effects of octreotide therapy on in-stent restenosis. [2003.07]
Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. [2003.07]
Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. [2003.06]
Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. [2003.05]
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. [2003.04]
Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial. [2003.03]
The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study. [2002.09.01]
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. [2002.09]
Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. [2002.09]
Octreotide enhances the accelerating effect of erythromycin on gastric emptying in healthy subjects. [2002.08]
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. [2002.07]
Effect of short-term octreotide therapy and total parenteral nutrition on the development of biliary sludge and lithiasis. [2002.05]
Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis. [2002.04]
A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. [2002.04]
Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. [2002.04]
|
